Osteologix Receives Positive Decision From Japan Patent Office

Osteologix, a Virginia-based biopharmaceutical company working in the area of musculoskeletal diseases, such as osteoporosis, has announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for Application Number 2006-504379 – Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts.

Reportedly, the patent claims cover the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the company’s osteoporosis drug candidate. With this Osteologix has now received patent protection for its osteoporosis therapy in the three major pharmaceutical markets in the world: Europe, United States and Japan. It has been reported that the patent’s 20-year term will expire in 2024.

Philip Young, president and CEO of Osteologix, said: We believe the intellectual property protections established by this patent in Japan, combined with our U.S. and European equivalents, will enable us to maximize the value of NB S101 in the most important pharmaceutical markets around the globe.